S&P Futures
4,066.25 +61.50 (+1.54%) Dow Futures
32,543.00 +384.00 (+1.19%) Nasdaq Futures
12,480.25 +235.50 (+1.92%) Russell 2000 Futures
1,816.00 +33.60 (+1.89%) Crude Oil
115.38 +1.18 (+1.03%) Gold
1,834.30 +20.30 (+1.12%)
Histogen Inc. (HSTO)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.1656 |
| Open | 0.1800 |
| Bid | 0.1600 x 1800 |
| Ask | 0.1649 x 1800 |
| Day's Range | 0.1575 - 0.1800 |
| 52 Week Range | 0.1500 - 1.2300 |
| Volume | |
| Avg. Volume | 3,117,263 |
| Market Cap | 7.957M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4930 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.25 |
- GlobeNewswire
Histogen Reports First Quarter 2022 Financial Results and Provides Business Update
Received $3.75 Million Payment from Allergan Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the first
- GlobeNewswire
Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen’s financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022. About Histogen Inc. Histogen Inc. is a clinical-stage ther
- GlobeNewswire
Histogen Announces Closing of $4.75 Million Private Placement
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced the closing of its previously announced private placement for the issuance and sale of 2,500 shares of Series A redeemable convertible preferred stock and 2,500 shares of Series B redeemable convertible preferred stock.
